Fig. 1: Survival and Response Rates. | Blood Cancer Journal

Fig. 1: Survival and Response Rates.

From: A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)

Fig. 1

Kaplan–Meier plot of PFS (a), OS (b), and response rates (c). αBest responses were attained in induction among patients who had received at least one dose of the study drug. βResponses among patients who had completed induction and autologous stem cell transplant. δResponses among patients who had completed induction, autologous stem cell transplant, and consolidation. εBest response attained during trial among all patients.

Back to article page